Law360, New York (January 22, 2013, 1:56 PM EST) -- A New Jersey federal judge on Thursday found that Dr. Reddy’s Laboratories Ltd. didn’t infringe a patent belonging to Sunovion Pharmaceuticals Inc. for its blockbuster drug Lunesta, finding that Dr. Reddy’s proposed generic version of the sleep aid is chemically different.
U.S. District Judge Dennis M. Cavanaugh granted Dr. Reddy’s move for summary judgment of noninfringement as to U.S. Patent No. 6,444,673 over its planned drug, saying that the generic doesn’t fall within the scope of Sunovion’s asserted claims for the '673 patent.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.